Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipel… Read more
Implantica AG (IMP-A-SDB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.034x
Based on the latest financial reports, Implantica AG (IMP-A-SDB) has a cash flow conversion efficiency ratio of -0.034x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.00 Million) by net assets (Skr89.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Implantica AG - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Implantica AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Implantica AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Implantica AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skillz Platform Inc
NYSE:SKLZ
|
-0.195x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
TVS Electronics Limited
NSE:TVSELECT
|
-0.125x |
|
China Tianrui Group Cement Company Limited
F:T18
|
0.021x |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
0.017x |
|
Eureka Acquisition Corp Class A Ordinary Share
NASDAQ:EURK
|
-0.006x |
|
ROCHE BOBOIS S.A. EO5
F:5RO
|
N/A |
|
ELK-Desa Resources Bhd
KLSE:5228
|
0.025x |
Annual Cash Flow Conversion Efficiency for Implantica AG (2017–2024)
The table below shows the annual cash flow conversion efficiency of Implantica AG from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr100.16 Million | Skr-22.75 Million | -0.227x | -42.70% |
| 2023-12-31 | Skr125.05 Million | Skr-19.91 Million | -0.159x | -43.75% |
| 2022-12-31 | Skr144.09 Million | Skr-15.96 Million | -0.111x | -54.39% |
| 2021-12-31 | Skr159.92 Million | Skr-11.47 Million | -0.072x | +20.48% |
| 2020-12-31 | Skr114.89 Million | Skr-10.36 Million | -0.090x | +70.89% |
| 2019-12-31 | Skr11.53 Million | Skr-3.57 Million | -0.310x | -28.35% |
| 2018-12-31 | Skr15.44 Million | Skr-3.73 Million | -0.241x | -43.78% |
| 2017-12-31 | Skr10.46 Million | Skr-1.76 Million | -0.168x | -- |